TrialBMC medical research methodology2025

Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma.

Christopher G Fawsitt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.